30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: ArthroCare

$60.9MM, flat

  • Sports Medicine $58.9MM, +2%
  • Other (includes spine) $2.0MM, -30%

 

  • Proprietary Sports Med sales in Americas +1%, due to higher Coblation sales for knee and hip arthroscopy, partially offset by lower average selling prices (-2% year over year)
  • Fixation product sales mostly unchanged in quarter
  • International Sports Med +7%, with direct markets +8% and comprising 84% of total International Sports Med revenue
  • Commenced resolution with Department of Justice of outstanding item related spine business; may be required to pay $30MM as part of Deferred Prosecution Agreement
  • Invested ~ $4MM in cash to acquire ~20% stake in OrthoSpace, developer of biodegradable balloon to treat shoulder rotator cuff injury; received distribution rights in certain ex-U.S. markets
  • 2H13 product launches include suture patching product portfolio expansion for shoulder and hip, extensions to MultiFIX suture anchors, limited release of CLS reconstruction system
  • Educated ~90 surgeons on Coblation during knee arthroscopy